Squarepoint’s Apellis Pharmaceuticals APLS Stock Holding History

Squarepoint’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,000	Closed	-$898K	–	3980
2023 Q4	$898K	Buy	+15,000	New	+$761K	﹤0.01%	2599

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Squarepoint's APLS Position: Q2 2026 in Review

Squarepoint sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 449,796 shares — an estimated $18.1M sold.

Squarepoint first reported a position in APLS in Q3 2018 and held it in 21 quarters. The position peaked at $18.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Squarepoint reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 449,796 Apellis Pharmaceuticals shares in Q2 2026, an estimated $18.1M.
Squarepoint first reported a position in Apellis Pharmaceuticals in Q3 2018 and held it in 21 quarters.
Squarepoint's Apellis Pharmaceuticals position peaked at $18.1M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.